Day: March 28, 2025

Helport AI to Host First Half Fiscal Year 2025 Financial Results Conference Call on Monday, March 31, 2025 at 4:30 p.m. Eastern Time

Written by Customer Service on March 28, 2025. Posted in Public Companies.

SINGAPORE and SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) — Helport AI Limited (NASDAQ: HPAI) (“Helport AI” or the “Company”), an AI technology company serving enterprise clients with intelligent customer communication software and services, will hold a conference call on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first half of fiscal year 2025 ended December 31, 2024, ongoing initiatives, and recent milestones. A press release detailing these results will be issued prior to the call. Chief Executive Officer and Chairman Guanghai Li, and President and Interim Chief Financial Officer Amy Fong, will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations...

GlobalTech Corporation Announces Fourth Quarter and Year End 2024 Results

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

Record revenue of $18 million for full-year 2024, up 72% over prior year RENO, Nev., March 28, 2025 (GLOBE NEWSWIRE) — GlobalTech Corporation (GTC, OTC:GTLK) (“GlobalTech” or the “Company”), a leading U.S.-based technology investment holding company, today announced financial results for the year ending December 31, 2024. Full-Year 2024 Financial Highlights:Net Revenue surged 72% in 2024, reaching $18.3 million, up from $10.6 million in the previous year. Operating Loss improved significantly, narrowing to $4.1 million in 2024, down from a loss of $10.5 million in 2023, positively impacted by strong revenue growth. As a percentage of revenue, operating loss improved to 22% in 2024, down from 99% in 2023, primarily due to revenue growing at a significantly faster rate than direct operating costs. Net Loss declined to $3.0 million...

Man Group PLC : Form 8.3 – LondonMetric Property plc

Written by Customer Service on March 28, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LondonMetric Property plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening...

Aptose Reports Year End 2024 Results and Corporate Highlights

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update. “During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed...

Base Carbon Announces Investor Call

Written by Customer Service on March 28, 2025. Posted in Public Companies.

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce the Company will host an investor update call on Tuesday, April 1, 2025, at 11:00 a.m. Eastern Time (EDT). The Company intends to release the 2024 year-end financial results on Monday, March 31, 2025. The management team will provide a business update in connection with the results and respond to investor questions via Zoom Webinar. Registration instructions are published below. The Company invites current and prospective shareholders to attend this business update call and Q&A session. DATE: Tuesday, April 1, 2025TIME: 11:00 a.m. EDTLOCATION: Zoom Webinar. To receive...

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Written by Customer Service on March 28, 2025. Posted in Public Companies.

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing agreed upon Investigational New Drug (IND) application-enabling activities for LX9851. Novo Nordisk will be responsible for filing the IND, all further...

Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under “ATLN” Announces Strategic Developments and Outlook; Targets $1 to $1.5 Billion Revenue from Both Organic Growth and M&A Initiatives in the Next 12 to 18 Months ENGLEWOOD CLIFFS, N.J., March 28, 2025 (GLOBE NEWSWIRE) — Atlantic International Corp. (“Atlantic” or the “Company”) (NASDAQ: ATLN), a leading provider of strategic staffing, outsourced services and workforce solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2024. Key Financial Highlights:Q4 2024 Revenue: Revenue for the fourth quarter was $129.5 million, representing an 11.5% increase from $116.2 million in Q4 2023. Q4 2024 Gross Profit: Gross profit for the quarter was $13.3 million, or 10.3% of revenue, compared to $12.6 million,...

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 Phase 1 enrollment in LAVA-1266 clinical trial underway Johnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024 Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth...

Super League Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Update on Strategic Discussions to Accelerate Path to Profitability and Diversify Revenues

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

~ Ann Hand to Support Strategic Alternative Initiatives as Executive Chair; President Matt Edelman Promoted to the Role of Chief Executive Officer ~ ~ Renowned Marketing and Advertising Executive Bant Breen Appointed to Board of Directors ~ SANTA MONICA, Calif., March 28, 2025 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a leader in redefining the gaming industry as a media channel, today released fourth quarter and full year 2024 financial results. Super League Executive Chair, Ann Hand Commented: “The last two years have presented Super League with a unique set of challenges that have tested our resolve. But make no mistake, our conviction and enthusiasm to seize the opportunity in front of us is unwavering. We have worked tirelessly to build our platform over the years and are confident we have the talent, grit and an actionable...

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

– Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma – – Commenced market launch and first commercial sales of Symvess – – Budget Impact Model for Symvess published in Journal of Medical Economics – – IND filing planned in 2025 to support first-in-human clinical study of small-diameter ATEV™ for coronary artery bypass grafting – – Conference call today at 8:30am ET – DURHAM, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the fourth quarter and year ended...

Day: March 28, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals